US Edition
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
- Taiho Oncology and Cullinan Therapeutics published positive Phase 1/2 REZILIENT1 trial results on June 2, 2025, in the Journal of Clinical Oncology.
- The trial enrolled 176 adult patients with recurrent or metastatic non-small cell lung cancer characterized by EGFR exon 20 insertion mutations, all of whom had previously received treatments such as platinum-based chemotherapy and amivantamab.
- Zipalertinib showed a confirmed overall objective response rate of 35.2%, median response duration of 8.8 months, and progression-free survival of 9.4 months in this population.
- Among individuals who received zipalertinib following only platinum-based chemotherapy , the overall response rate was 40% with a median duration of response of 8.8 months; in a subgroup of those with brain metastases, the confirmed response rate was 30.9% with a median duration of 8.3 months.
- Zipalertinib remains investigational but has FDA Breakthrough Therapy Designation, and ongoing Phase 3 REZILIENT3 recruitment aims to confirm its clinical benefit in this setting.
Insights by Ground AI
Does this summary seem wrong?
24 Articles
24 Articles
All
Left
4
Center
7
Right
3
Bennington Banner+23 Reposted by 23 other sources
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase…
Coverage Details
Total News Sources24
Leaning Left4Leaning Right3Center7Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 29%
C 50%
R 21%
Factuality
To view factuality data please Upgrade to Premium
